newsfilter
← Latest News
ACCESS Newswire·

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Company has one year of cash to fund operationsCompany advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy data in